Will Eli Lilly's blockbuster obesity drug be available in India in 2025?
Tirzepatide had received approval in a single-dose prefilled pen format in January 2024 for use as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes, provided
Lilly adds another sales channel for obesity drug Zepbound
"Offering Zepbound single-dose vials…through another platform to LillyDirect will help ensure broader availability of rigorously tested, FDA-approved and regulated obesity treatment,” said Patrik Jonsson, president of Lilly Cardiometabolic Health and Lilly USA.
Lilly CEO predicts obesity-treatment Zepbound will become drugmaker’s top drug by 2025
David Ricks told a lunch audience at the Economic Club of Washington, D.C., that Zepbound could quickly become the most popular drug in the 148-year-old company’s history.
Lilly to test obesity drugs to treat addiction in 2025
Eli Lilly and Co. will begin studies to see if its blockbuster weight-loss medicines are also effective at controlling addictive behaviors like alcohol abuse, smoking and drug addiction, Chief Executive Officer Dave Ricks said.
What can't weight-loss meds do? Eli Lilly is going to test Zepbound as a treatment for addiction
Eli Lilly (LLY), the pharma giant that produces the popular weight-loss drug Zepbound, said it plans to test the blockbuster drug as a treatment for alcohol and drug addiction starting next year.
rheumatologyadvisor19h
Tirzepatide Bests Semaglutide in Head-to-Head Weight Loss Trial
The most common adverse events reported with both treatments were mild to moderate gastrointestinal-related side effects.
GlobalData on MSN2d
BioAge halts ongoing Phase II trial of obesity drug due to liver concerns
In the trail, 11 participants in the azelaprag group exhibited transaminase elevations without significant symptoms.
BioSpace2d
BioAge Crashes After Axing Phase II Obesity Study
The discontinuation of STRIDES is a rare stumble for the next-generation obesity field and comes just weeks after Amgen ...
Science News5d
How the weight loss drug tirzepatide is also helping heart failure patients
Data continue to show that tirzepatide, called Mounjaro for type 2 diabetes and Zepbound for weight loss, is safe and effective, but side effects remain.
BioPharma Dive4d
BioAge shares tumble after decision to halt obesity drug study
The biotech disclosed Friday plans to terminate a Phase 2 study testing azelaprag with tirzepatide for weight loss following ...
BMJ6d
Tirzepatide: Obesity injection will get phased rollout to avoid overwhelming GPs
GP leaders have warned that the rollout of the weight loss drug tirzepatide (Mounjaro, Eli Lilly) will still have ...
National Institute for Health and Care Excellence6d
Tirzepatide - a new chapter in obesity treatment
Tirzepatide has been shown in clinical trials to be more effective than diet and exercise support alone, and when compared ...
STAT6d
Pharmalittle: We’re reading about U.K. restricting Lilly’s obesity drug, pharma layoffs, and more
The U.K. will start offering Eli Lilly’s weight loss drug next year, but will restrict the medicine to people with the ...
BioSpace5d
Lilly Pumps $3B Into Wisconsin Site as Compounders Close In on Tirzepatide
Eli Lilly is aggressively ramping up its manufacturing capacity for tirzepatide as compounding pharmacies continue to ...